SNYNF — Sanofi
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1121404 ·
Last close
$79.96
Market Cap
$95.80B
52W High
$106.34
52W Low
$79.75
ADV30
5,110
Next earnings
2026-10-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 12,300,000,000 | 9,283,000,000 | 2,384,000,000 | 343,000,000 | 129,060,000,000 | 6,350,000,000 | 59,493,000,000 |
| Mar 2026 | 11,244,000,000 | 8,106,000,000 | 2,269,000,000 | 1,614,000,000 | 128,024,000,000 | 5,544,000,000 | 54,881,000,000 |
| Dec 2025 | 12,205,000,000 | 8,449,000,000 | 1,630,000,000 | -801,000,000 | 126,805,000,000 | 7,657,000,000 | 55,095,000,000 |
| Sep 2025 | 13,170,000,000 | 9,758,000,000 | 3,785,000,000 | 2,802,000,000 | 129,794,000,000 | 8,906,000,000 | 56,261,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$11,837,000,000
Investing CF
$-13,293,000,000
Financing CF
$-7,050,000,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$4.21
As of
2026-08-09
Yahoo Snapshot (yfinance, live)
Total Revenue
$48,918,999,040
EBITDA
$13,543,000,064
Free Cash Flow
$6,298,999,808
Enterprise Value
$118,247,759,872
Total Cash
$6,350,000,128
Total Debt
$23,576,000,512
Shares Out
1,198,068,685
Trailing EPS
$3.77
Book Value
$67.20
ROE
5.7%
ROA
5.1%
Div Yield
5.76%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 46,716,000,000 | 9,597,000,000 | 7,813,000,000 | 126,805,000,000 | 55,095,000,000 | 71,376,000,000 | 10,750,000,000 |
| Dec 2024 | 44,286,000,000 | 8,923,000,000 | 5,560,000,000 | 132,798,000,000 | 54,941,000,000 | 77,507,000,000 | 9,081,000,000 |
| Dec 2023 | 41,618,000,000 | 8,691,000,000 | 5,400,000,000 | 126,464,000,000 | 52,111,000,000 | 74,040,000,000 | 10,258,000,000 |
| Dec 2022 | 40,561,000,000 | 10,926,000,000 | 8,371,000,000 | 126,722,000,000 | 51,570,000,000 | 74,784,000,000 | 10,526,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$9.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GLAXF | GSK plc | $94.45B | $23.58 | — |
| SNY | Sanofi | $98.67B | $41.18 | — |
| GSK | GSK plc | $99.54B | $49.70 | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | $76.08B | $752.25 | — |
| NONOF | NOVO NORDISK A S | $129.28B | $38.66 | — |
News headlines (Yahoo Finance, 1h cache)
What Bavarian Nordic’s next CEO is up against
2026-09-28 12:50 · Yahoo
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
2026-09-25 13:30 · Yahoo
Why Is Sanofi (ENXTPA:SAN) Reshaping Its Business Around Vaccines And Mature Medicines?
2026-09-23 21:20 · Yahoo
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
2026-09-23 15:20 · Yahoo
European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance
2026-09-23 14:52 · Yahoo
Is Regeneron Stock a Bargain Below $800?
2026-09-22 19:35 · Yahoo
AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’
2026-09-22 19:26 · Yahoo
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going
2026-09-22 12:57 · Yahoo
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine
2026-09-22 11:02 · Yahoo
Capitalize on the Orphan Drug Revenue Shift: Benchmark Novartis, Roche, Pfizer, Sanofi and AstraZeneca to Secure High-Value Growth Before Rivals Move First
2026-09-22 08:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.